Peptides went from obscure research compounds to dinner-party conversation in about eighteen months. GLP-1s cracked the door; a long tail of compounds most people can't pronounce walked through it. What hasn't kept up is the quality of the conversation — overclaiming on one side, blanket dismissal on the other, and very little in between for someone who's simply curious and wants a straight answer.

​

Julius Ritter is the founder of the California Peptide Club, a private community of researchers, founders, and practitioners now expanding nationwide, and President of AGI House SF, a technical hacker house whose residents have gone on to build several billion-dollar companies. He previously scaled BASIS Health, a longevity food company, across two continents, was the first growth hire at Superpower, and exited an AI company. His work has been featured in Bloomberg, Business Insider, and The SF Standard.

The Science — What peptides actually are, what the (pre-)clinical data shows, and how to weigh the anecdotal reports that dominate the conversation.

The History, Zeitgeist & Future — How we got here, why peptides are having a moment, and what the space looks like ten years out.